vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $11.5M, roughly 1.6× TRANSACT TECHNOLOGIES INC). On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 11.9%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 3.5%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
SCYX vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $11.5M |
| Net Profit | $12.3M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | 56.3% | -10.1% |
| Net Margin | 65.7% | — |
| Revenue YoY | 1808.5% | 11.9% |
| Net Profit YoY | 376.5% | — |
| EPS (diluted) | $0.25 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $11.5M | ||
| Q3 25 | $334.0K | $13.2M | ||
| Q2 25 | $1.4M | $13.8M | ||
| Q1 25 | $257.0K | $13.1M | ||
| Q4 24 | $977.0K | $10.2M | ||
| Q3 24 | $660.0K | $10.9M | ||
| Q2 24 | $736.0K | $11.6M | ||
| Q1 24 | $1.4M | $10.7M |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $-8.6M | $15.0K | ||
| Q2 25 | $-6.9M | $-143.0K | ||
| Q1 25 | $-5.4M | $19.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.8M | $-551.0K | ||
| Q2 24 | $-14.5M | $-319.0K | ||
| Q1 24 | $411.0K | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | 56.3% | -10.1% | ||
| Q3 25 | -2516.5% | 0.1% | ||
| Q2 25 | -701.0% | -1.9% | ||
| Q1 25 | -3350.2% | -0.1% | ||
| Q4 24 | — | -10.3% | ||
| Q3 24 | -1563.6% | -7.7% | ||
| Q2 24 | -1255.0% | -3.8% | ||
| Q1 24 | -692.5% | -12.2% |
| Q4 25 | 65.7% | — | ||
| Q3 25 | -2572.2% | 0.1% | ||
| Q2 25 | -504.8% | -1.0% | ||
| Q1 25 | -2097.7% | 0.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -425.5% | -5.1% | ||
| Q2 24 | -1964.4% | -2.8% | ||
| Q1 24 | 29.9% | -9.7% |
| Q4 25 | $0.25 | $-0.11 | ||
| Q3 25 | $-0.17 | $0.00 | ||
| Q2 25 | $-0.14 | $-0.01 | ||
| Q1 25 | $-0.11 | $0.00 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | $-0.06 | $-0.06 | ||
| Q2 24 | $-0.30 | $-0.03 | ||
| Q1 24 | $0.01 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $31.1M |
| Total Assets | $59.0M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $20.4M | ||
| Q3 25 | $37.9M | $20.0M | ||
| Q2 25 | $44.8M | $17.7M | ||
| Q1 25 | $40.6M | $14.2M | ||
| Q4 24 | $59.3M | $14.4M | ||
| Q3 24 | $68.8M | $11.3M | ||
| Q2 24 | $73.0M | $11.1M | ||
| Q1 24 | $80.2M | $10.6M |
| Q4 25 | $49.4M | $31.1M | ||
| Q3 25 | $36.4M | $31.8M | ||
| Q2 25 | $44.5M | $31.3M | ||
| Q1 25 | $50.5M | $30.9M | ||
| Q4 24 | $55.1M | $30.6M | ||
| Q3 24 | $58.5M | $38.4M | ||
| Q2 24 | $60.4M | $38.5M | ||
| Q1 24 | $74.1M | $38.6M |
| Q4 25 | $59.0M | $44.8M | ||
| Q3 25 | $51.1M | $45.0M | ||
| Q2 25 | $60.7M | $44.5M | ||
| Q1 25 | $67.9M | $44.2M | ||
| Q4 24 | $90.6M | $44.0M | ||
| Q3 24 | $99.0M | $50.5M | ||
| Q2 24 | $107.8M | $50.4M | ||
| Q1 24 | $118.3M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $609.0K |
| Free Cash FlowOCF − Capex | — | $589.0K |
| FCF MarginFCF / Revenue | — | 5.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $609.0K | ||
| Q3 25 | $-8.7M | $3.6M | ||
| Q2 25 | $-7.5M | $3.6M | ||
| Q1 25 | $-7.5M | $-161.0K | ||
| Q4 24 | $-24.0M | $2.4M | ||
| Q3 24 | $765.0K | $327.0K | ||
| Q2 24 | $-10.9M | $636.0K | ||
| Q1 24 | $-4.0M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
TACT
Segment breakdown not available.
